NeuroMetrix Announces Highly Positive Industry and Media Reaction to Quell® Wearable Pain Relief Technology at the 2016 Consumer Electronics Show

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include:

• Quell was selected as one of 10 finalists in the CES Last Gadget Standing competition
• NeuroMetrix was selected to participate in two panel discussions - "The Roadmap to FDA Approval" and "The Future of Wearables"
• NeuroMetrix announced FDA 510(k) clearance for the next generation Quell
• Quell was covered in over 27 news outlets such as:
  • Newsweek - This FDA-approved wearable says it relieves chronic pain without any drugs
  • Boston Globe - FDA approves upgrade to Quell, a dongle that zaps away pain
  • Drug Store News - Quell makes top 10 in CES' Last Gadget Standing event
  • Consumer Reports - Quell wearable might deliver chronic pain relief without drugs
  • GetConnected - Tech heavy pain relief that's drug free!
  • Pain Medicine News - Upgraded wearable pain relief device cleared by FDA
  • The Source - Multi-billion dollar wearables tech sector is the star of CES 2016

"We were pleased with the response to Quell at CES. The interest in Quell continues to grow, and there is clearly a need for wearable technology that makes a meaningful and clear difference in people's lives," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "In our second year at CES, the transformation of NeuroMetrix into a consumer health technology company is gaining momentum."

Quell is designed for people with a wide range of chronic pain conditions. The latest version of Quell gives users the option to control their therapy via a mobile app and includes several additional enhancements including extended battery life and advanced sleep tracking. It will be available in March 2016.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160114005185/en/

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media